Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Monoclonal Gammopathy of Renal Significance

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Monoclonal Gammopathy of Renal Significance cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 2CCC
FILGRASTIM
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Bortezomib
Memorial Sloan Kettering Cancer Center
Phase 2CCC
DARATUMUMAB
Memorial Sloan Kettering Cancer Center
Phase 2CCC
PREDNISONE TABLETS
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Inno-206
Memorial Sloan Kettering Cancer Center
Phase 2CCC

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →